A new heart stent, or scaffold, which actually absorbs into the system of the body and has been approved in Europe in January this year, has shown promising results from two Phase. The FDA approval of the United States seems to be a little ‘time away though.For a year, Abbott ABSORB apparatus shown no cases of blood clots . Above all, the vessels of patients who were evaluated for vasomotor function, nearly all showed signs of vasomotor tone at one year, indicating that the movement of vessels was observed in the arteries of these patients their ships are no longer bound by the scaffold, which had begun to be metabolized.
‘The data for one year in these patients confirm earlier results seen at six and nine months the unit ABSORB has the potential to effectively treat coronary artery disease, with the ability to restore the natural function of the ship in a way not possible with metal implants permanent. In addition, the loss of a year’s delay seen with Absorb is similar to that seen in a series of drug-eluting stents, which is an encouraging sign that the scaffold, as bioresorbable ABSORB might be able to provide the performance capabilities of a metal stent drugs, but with the added benefit of a possible dissolution. ‘
The device is designed to restore blood flow by opening a clogged vessel and providing support to the tank. Once the ship can remain open without the additional support, Absorb is designed to metabolize slowly and eventually be reabsorbed by the body.
Coronary heart disease is usually caused by a disease called atherosclerosis, which occurs when fats and other substances form a plaque on the artery walls. This causes them to shrink. As the arteries narrow coronary blood flow, the heart can slow or stop.
Coronary heart disease is the leading cause of death in the United States for men and women.
‘The positive clinical results of a year of the ABSORB trial provide support for the clinical performance of the device and its potential to change the way it is treated coronary artery disease. Abbott is committed to continuing to build the body of clinical evidence to support of this new therapy, and we expect that further clinical trials this year. ‘
Patrick W. Serruys, MD, Ph.D.
, professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, Netherlands Comments: